237 related articles for article (PubMed ID: 29666232)
1. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
Powell Gray B; Kelly L; Ahrens DP; Barry AP; Kratschmer C; Levy M; Sullenger BA
Proc Natl Acad Sci U S A; 2018 May; 115(18):4761-4766. PubMed ID: 29666232
[TBL] [Abstract][Full Text] [Related]
2. An Aptamer for Broad Cancer Targeting and Therapy.
Powell Gray B; Song X; Hsu DS; Kratschmer C; Levy M; Barry AP; Sullenger BA
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142831
[TBL] [Abstract][Full Text] [Related]
3. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
Burns KE; Hensley H; Robinson MK; Thévenin D
Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
[TBL] [Abstract][Full Text] [Related]
7. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma.
Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W
ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139
[TBL] [Abstract][Full Text] [Related]
8. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
[TBL] [Abstract][Full Text] [Related]
9. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
10. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
11. A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
Speransky S; Serafini P; Caroli J; Bicciato S; Lippman ME; Bishopric NH
Breast Cancer Res Treat; 2019 Jul; 176(2):271-289. PubMed ID: 31006104
[TBL] [Abstract][Full Text] [Related]
12. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
13. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
Akaiwa M; Dugal-Tessier J; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
[TBL] [Abstract][Full Text] [Related]
15. Construction of Bispecific Aptamer-Drug Conjugate by a Hybrid Chemical and Biological Approach.
Sun Y; Gao F; Yang C; Li Y; Jin C; Xie S; Lv C; Ding D; Han D; Li J; Wang R; Tan W
Bioconjug Chem; 2020 May; 31(5):1289-1294. PubMed ID: 32223180
[TBL] [Abstract][Full Text] [Related]
16. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
[TBL] [Abstract][Full Text] [Related]
17. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
19. Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth.
Cunningham D; Parajuli KR; Zhang C; Wang G; Mei J; Zhang Q; Liu S; You Z
Prostate; 2016 Nov; 76(15):1420-30. PubMed ID: 27325602
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
Burns KE; Robinson MK; Thévenin D
Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
